Scientific Advisory Board

is Chief Scientific Officer at ProMIS Neurosciences and Professor of Medicine at the University of British Columbia, where he holds the Canada Research Chair in Neurodegeneration and Protein Misfolding Diseases and serves as the Director of the UBC ALS Centre. Dr. Cashman is recognized as a pioneer in the field of prions and their role in the development of neurodegenerative diseases, in particular ALS and AD. Neil Cashman is co-chair of the SAB.

is Medical Director and Principal Investigator of Toronto Memory Program, an independent medical facility for dementia care and research. Her memory clinic and dementia clinical trials program are the largest and most active in Canada and have contributed substantially to patient care and to global clinical trial cohorts. Dr. Cohen holds an FRCPC in neurology from the Royal College of Physicians of Canada and a fellowship in Behavioural Neurology from the University of Toronto.

Dr. Alain Dagher, MD, FRCP (C) has been an attending neurologist at the Montreal Neurological Institute, McGill University, since 1997, specializing in movement disorders and functional brain imaging. His research has two components: (1) understanding neurodegenerative diseases including Parkinson's disease; (2) identifying the neural mechanisms that support motivated decision-making, with application to addiction and obesity. His lab uses functional brain imaging in human subjects, including anatomical and functional magnetic resonance imaging, positron emission tomography and transcranial magnetic stimulation. His group has recently investigated the topography of neurodegeneration in PD to test propagation models, develop biomarkers, and stratify patients to predict disease outcomes. Research focuses on Parkinson's disease, stress, addiction, and obesity. He has published extensively on brain imaging (200+ publications, >50 on Parkinson’s Disease) and is senior editor of Neuroimage.

is Professor of Cell Biology and Anatomy and Director of the Center for Genetic Diseases at the Chicago Medical School, Rosalind Franklin University of Medicine and Science. Dr. Hastings’ expertise is in RNA biology and antisense technology. Her lab is leading advances in the field of RNA splicing and how the process can be harnessed to treat disease. Dr. Hastings has utilized small molecules and antisense oligonucleotides to modulate aberrant splicing associated with spinal muscular atrophy (SMA), Usher syndrome, Alzheimer’s disease, Parkinson’s disease, Batten disease and cystic fibrosis. She received her Ph.D. at Marquette University and was a post-doctoral fellow at Cold Spring Harbor Laboratory.

Dr. Carsten Korth, MD PhD is a licensed psychiatrist in molecular research from the University of Düsseldorf, Germany. He was trained at the Max Planck Institute for Psychiatry, Germany, and the University of California San Francisco. He has pioneered the notion that aberrant proteostasis and protein misfolding could be key to biologically define subsets of schizophrenia.

is Associate Dean for Neurosciences Initiatives, Distinguished Professor of Neurosciences, and Florence Riford Chair for Alzheimer's Disease at the University of California, San Diego where he also serves as Executive Director of the university’s Down Syndrome Center for Research and Treatment. Dr. Mobley’s research focuses on the neurobiology of neuronal dysfunction in developmental and age-related disorders of the nervous system. He has conducted pioneering work on the neurobiology of Alzheimer’s disease and Down syndrome.

is Director of The Neuro (Montreal Neurological Institute-Hospital), Chair of the Department of Neurology and Neurosurgery of McGill University, Director of the Department of Neuroscience of McGill University Health Centre, and co-founder of the Tanenbaum Open Science Institute. Over the last two decades, Dr. Rouleau and his team have focused on identifying genes causing neurological and psychiatric diseases, including autism, amyotrophic lateral sclerosis, hereditary neuropathies, epilepsy and schizophrenia, as well as providing a better understanding of the molecular mechanisms that lead to the symptoms and signs of these diseases. An MD graduate from the University of Ottawa, Dr. Rouleau completed his PhD in genetics at Harvard University and post-graduate work at The Neuro and Massachusetts General Hospital. He has dedicated his career to advancing research and clinical care for neurological patients and to training the next generation of neuroscientists.

is a professor in the Institute of Psychiatry, Psychology and Neuroscience at King’s College London, and Honorary Consultant psychiatrist, South London and the Maudsley NHS Trust. His current projects and collaborations include the LonDownS consortium, funded by the Wellcome Trust/ MRC, to study the neurobiology of Alzheimer’s Disease in Down syndrome to understand the underlying factors that may influence variation in age of onset of symptoms. His research in Down syndrome includes investigation of biomarkers of cognitive decline including those related to excess amyloid production, oxidative stress, and neurodegeneration. His group also conducts neuroimaging studies using high-density EEG, MRI and fNIRS. He has been an investigator on clinical trials of new drug treatment options in Down syndrome, fragile X syndrome and autism.

is Professor, Pathology and Laboratory Medicine, University of British Columbia, and has built an internationally recognized research program that focuses on neurological disease, with a particular emphasis on Alzheimer’s Disease and Traumatic Brain Injury.  Her formal affiliations with the Djavad Mowafaghian Centre for Brain Health, Vancouver Coastal Health Research Institute, the UBC School of Biomedical Engineering and the International Collaboration on Repair Discoveries attest to the interdisciplinary nature of her research program and training environment. She holds a variety of national and international leadership positions, including executive positions in the Canadian Traumatic Brain Injury Research Consortium, the Canadian Concussion Network, and the International Initiative on Traumatic Brain Injury Research. Dr. Wellington has also served in leadership roles in the Cure Alzheimer Fund Research Leaders Group and the Canadian Consortium for Neurodegeneration in Aging.  She is currently leading major national initiatives in neurology fluid biomarker innovation, spanning multiple neurodegenerative, neuroinflammatory and neurotrauma indications from community-based studies to neurocritical care. Dr. Wellington obtained her PhD at the University of British Columbia (UBC) and performed postdoctoral fellowships at Harvard Medical School, the University of Calgary, and UBC.